- Home
- BIRD vs PLRX Comparison
BIRD vs PLRX Comparison
Compare BIRD & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- PLRX
- Stock Information
- Founded
- BIRD 2015
- PLRX 2015
- Country
- BIRD United States
- PLRX United States
- Employees
- BIRD N/A
- PLRX N/A
- Industry
- BIRD Apparel
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- PLRX Health Care
- Exchange
- BIRD Nasdaq
- PLRX Nasdaq
- Market Cap
- BIRD 99.0M
- PLRX 84.7M
- IPO Year
- BIRD 2021
- PLRX 2020
- Fundamental
- Price
- BIRD $10.71
- PLRX $1.16
- Analyst Decision
- BIRD Buy
- PLRX Hold
- Analyst Count
- BIRD 2
- PLRX 10
- Target Price
- BIRD $9.50
- PLRX $9.79
- AVG Volume (30 Days)
- BIRD 119.2K
- PLRX 1.4M
- Earning Date
- BIRD 08-06-2025
- PLRX 08-06-2025
- Dividend Yield
- BIRD N/A
- PLRX N/A
- EPS Growth
- BIRD N/A
- PLRX N/A
- EPS
- BIRD N/A
- PLRX N/A
- Revenue
- BIRD $182,544,000.00
- PLRX N/A
- Revenue This Year
- BIRD N/A
- PLRX N/A
- Revenue Next Year
- BIRD $5.04
- PLRX N/A
- P/E Ratio
- BIRD N/A
- PLRX N/A
- Revenue Growth
- BIRD N/A
- PLRX N/A
- 52 Week Low
- BIRD $3.93
- PLRX $1.10
- 52 Week High
- BIRD $18.33
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- BIRD 56.66
- PLRX 34.14
- Support Level
- BIRD $8.53
- PLRX $1.23
- Resistance Level
- BIRD $11.68
- PLRX $1.43
- Average True Range (ATR)
- BIRD 1.35
- PLRX 0.11
- MACD
- BIRD -0.21
- PLRX -0.02
- Stochastic Oscillator
- BIRD 41.01
- PLRX 3.92
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.